目的:研究柚皮素对人视网膜色素上皮细胞(ARPE-19)和人脐静脉内皮细胞(HUVEC)的抗氧化作用。方法:采用MTT的方法检测ARPE-19和HUVEC细胞的生存率及增殖率。结果:3,10mg/L柚皮素能显著增加ARPE-19细胞的增殖率达10.8%和11.4%。10mg/L柚皮素能提高ARPE-19细胞在缺氧,0.3mmol/LNaN3及200μmol/LH2O2条件下的生存率分别为55.2%,69.2%及50.3%。1mg/L柚皮素能提高ARPE-19细胞在50μmol/Lt-BHP和30mg/LNaIO3条件下的生存率达20.2%和30.4%。30mg/L柚皮素能够促进ARPE-19细胞在50μmol/Lt-BHP条件下的增殖率达32.2%,而1mg/L柚皮素可以提高30,100,300mg/LNaIO3处理的ARPE-19细胞的增殖率达30.3%,10.3%及18.5%。3,10及30mg/L柚皮素抑制HUVEC的增殖率分别为23.9%,70.4%及77.9%。1,3mg/L柚皮素能提高HUVEC细胞在缺氧条件下的生存率达10.7%和13.1%,以及提高在300mg/LNaIO3条件下的生存率达41.2%和37.7%。3mg/L柚皮素能提高HUVEC细胞在200,400μmol/LH2O2条件下的生存率达20.1%和21.5%。结论:柚皮素能够促进ARPE-19细胞的增殖率,抑制HU-VEC生长,同时对这两种细胞均有抗氧化作用。因此,柚皮素是治疗老年黄斑变性的很有前景的候选药物。 Objective: To study the anti-oxidation effect of naringenin on human retinal pigment epithelial cells (ARPE-19) and human umbilical vein endothelial cells (HUVECs). Methods: The survival rate and proliferation rate of ARPE-19 and HUVEC cells were detected by MTT method. Results: 3, 10mg / L naringenin significantly increased ARPE-19 cell proliferation rate of 10.8% and 11.4%. The survival rate of ARPE-19 cells treated with 10mg / L naringenin was 55.2%, 69.2% and 50.3% respectively under hypoxia, 0.3mmol / LNaN3 and 200μmol / LH2O2. 1mg / L naringenin increased ARPE-19 cells survival rate of 20.2% and 30.4% under 50μmol / Lt-BHP and 30mg / LNaIO3 conditions. The proliferation rate of ARPE-19 cells treated with 30mg / L naringenin was 32.2% at 50μmol / Lt-BHP, while the proliferation of ARPE-19 cells treated with 30mg / L naringenin at 30, 100 and 300mg / 30.3%, 10.3% and 18.5% respectively. The proliferation rates of 3, 10 and 30 mg / L naringenin on HUVEC were 23.9%, 70.4% and 77.9%, respectively. Naringenin at 1,3 mg / L increased the survival rate of hypodermic HUVEC cells by 10.7% and 13.1%, and increased the survival rate of HUVEC cells by 41.2% and 37.7% under 300mg / L NaO3. 3mg / L naringenin can improve the survival rate of HUVEC cells under the conditions of 200,400μmol / LH2O2 up to 20.1% and 21.5%. Conclusion: Naringenin can promote the proliferation rate of ARPE-19 cells and inhibit the growth of HU-VEC cells, meanwhile both of them have anti-oxidative effects. Therefore, naringenin is a promising candidate for the treatment of age-related macular degeneration.